# 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

> **NCT01733875** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 65 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CC-220 0.03 mg
- **DRUG:** CC-220 0.1 mg
- **DRUG:** CC-220 0.3 mg
- **DRUG:** CC-220 1 mg
- **DRUG:** CC-220 2 mg
- **DRUG:** Placebo
- **DRUG:** CC-220
- **DRUG:** CC-220
- **DRUG:** CC-220

## Key facts

- **NCT ID:** NCT01733875
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-01
- **Primary completion:** 2013-10-09
- **Final completion:** 2013-10-09
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733875, "2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01733875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*